Chile’s National Childhood Cancer Registry Tracks Rising Incidence and Better Survival
Chile’s National Childhood Cancer Registry offers one of the clearest national pictures yet of pediatric cancer surveillance in a middle-income setting. Between 2007 and 2023, the registry captured 8,821 incident cancers in children aged 0 to 14 years, allowing investigators to map incidence, mortality, survival, and registry quality in a single population-based framework. The findings show a modest but measurable rise in incidence, a steady improvement in survival, and a mortality trend that moved downward without reaching statistical significance.
The epidemiology is familiar in broad outline, but the scale and completeness of the data give it unusual weight for Latin America. Childhood cancer registries across the region continue to struggle with under-registration, uneven coverage, and variable data quality. RENCI was built to address those gaps, and this analysis shows what a functioning national registry can reveal when coverage is complete and case ascertainment is high.
Leukaemia remained the dominant diagnosis throughout the study period. Incidence reached 58.6 per million, followed by central nervous system tumors at 24.8 per million and lymphomas at 12.7 per million. Those rankings mirror the classic pediatric cancer distribution seen in many settings, where hematologic malignancies and brain tumors account for much of the burden. In clinical terms, the pattern points to the persistent need for diagnostic access, timely referral pathways, and pediatric oncology services capable of managing both systemic and neuro-oncologic disease.
Incidence rose from 137.4 to 143.0 per million, with an annual average percent change of 1.36% and a 95% confidence interval of 0.5 to 2.4. A slow increase in recorded incidence can reflect several different realities at once: improved ascertainment, better access to diagnostic workup, more complete registration, or a genuine epidemiologic shift. In a registry that achieved complete national coverage, the most likely explanation is not a sudden surge in disease alone, but a system that is finding cases more effectively than before. For pediatric cancer control, better detection is not a trivial artifact; it is often the first sign that children who once disappeared into unmet need are now entering formal care.
Five-year observed survival improved from 71.4% in 2007 to 2011 to 80.5% in 2020 to 2023. That change is clinically meaningful. Pediatric cancer survival improves when diagnosis happens earlier, treatment starts faster, supportive care is stronger, and abandonment of therapy declines. Better survival in a national registry therefore reflects more than oncology drug delivery alone. It points to the structure around treatment: pathology services, imaging, infection control, transfusion support, and continuity of follow-up. The registry does not isolate which of those gains drove the improvement, but the direction of travel is consistent with broader health-system strengthening.
Mortality moved from 36.3 to 25.7 per million between 2002 and 2021, with an annual average percent change of -0.57% and a confidence interval that crossed zero. The decline is encouraging, even if the trend did not meet statistical significance. Mortality often lags behind incidence and survival because deaths reflect both disease biology and the speed at which a health system responds once cancer is suspected. In childhood cancer, a falling mortality curve usually means that more children are surviving long enough to benefit from curative therapy and late-effect monitoring. It also means fewer families are facing the abrupt, catastrophic loss that still marks pediatric oncology in under-resourced settings.
RENCI’s quality metrics help explain why these trends deserve attention. The registry achieved 100% national coverage, with an MV% of 93.5% and a DCO% of 0.7%. Those figures sit comfortably within high-quality registry performance: a low death-certificate-only proportion suggests the database is not relying heavily on mortality records to reconstruct incidence, and a high percentage of morphologically verified cases indicates strong diagnostic confirmation. In practical terms, the registry is doing the hard epidemiologic work that makes national planning possible. Without that level of data integrity, policymakers are left guessing about burden, service needs, and regional inequities.
Why Registry Quality Changes Cancer Control
A childhood cancer registry is more than a counting tool. It is the infrastructure that lets health ministries see whether treatment access is expanding, whether survival is improving, and whether mortality is falling in step with clinical investment. In settings where case ascertainment is incomplete, policy can be shaped by the loudest institutions rather than the true national burden. RENCI’s performance shows that a middle-income country can build a registry that meets international quality expectations and still generate policy-relevant epidemiology.
The findings also matter because pediatric cancer control is increasingly judged by systems outcomes rather than isolated treatment wins. A child with acute leukemia can survive only if diagnosis occurs quickly enough to prevent early death, if chemotherapy is delivered consistently, and if complications are managed aggressively. The same logic applies to brain tumors and lymphomas, where delays in referral or imaging can erase the benefit of available therapy. Chile’s experience suggests that surveillance and care delivery are moving in the same direction, even if unevenly and gradually.
Limits in a Descriptive National Dataset
This remains a descriptive study, and the design cannot prove why incidence rose or why survival improved. Temporal associations are informative, but they are not causal proof. Changes in diagnostic intensity, reporting practices, treatment access, and population structure can all influence the trends seen in a registry-based analysis.
Even so, the dataset carries real operational value for other low- and middle-income countries. It shows what a mature registry can provide: credible national incidence, survival estimates over time, mortality trends, and a framework for evaluating data quality against IARC standards. For countries still building childhood cancer surveillance, the message is not abstract. Reliable cancer control starts with knowing who is being diagnosed, where they are diagnosed, and whether they survive long enough to complete treatment.
Chile’s registry now supplies that foundation. The remaining challenge is converting surveillance strength into faster diagnosis, more equitable treatment access, and further gains in survival for children with cancer.